| Literature DB >> 21474923 |
Donn M Stewart1, Roshan Ramanathan, Siddhartha Mahanty, Daniel P Fedorko, John E Janik, John C Morris.
Abstract
A 55-year-old woman with human T-cell lymphotropic virus type-1 (HTLV-1)-associated adult T-cell leukemia (ATL) and a history of previously treated Strongyloides stercoralis infection received anti-CD52 monoclonal antibody therapy with alemtuzumab on a clinical trial. After an initial response, she developed ocular involvement by ATL. Alemtuzumab was stopped and high-dose corticosteroid therapy was started to palliate her ocular symptoms. Ten days later, the patient developed diarrhea, vomiting, fever, cough, skin rash, and a deteriorating mental status. She was diagnosed with disseminated S. stercoralis. Corticosteroids were discontinued and the patient received anthelmintic therapy with ivermectin and albendazole with complete clinical recovery.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21474923 PMCID: PMC3080579 DOI: 10.1159/000324799
Source DB: PubMed Journal: Acta Haematol ISSN: 0001-5792 Impact factor: 2.195